{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:23:34Z","timestamp":1760300614754,"version":"3.37.3"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T00:00:00Z","timestamp":1631923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T00:00:00Z","timestamp":1631923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"national institute on aging","doi-asserted-by":"publisher","award":["R01 AG068192","R01 AG034676"],"award-info":[{"award-number":["R01 AG068192","R01 AG034676"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01 AR46849"],"award-info":[{"award-number":["R01 AR46849"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Louis V. Gerstner, Jr. Fund at Vanguard Charitable"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To evaluate the association between statin use and the risk of developing rheumatoid arthritis (RA) in a large, US case-control study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Using the OptumLabs Data Warehouse, RA cases were identified as patients aged \u226518 years with \u22652 RA diagnoses between January 1, 2010 and June 30, 2019 and \u22651 prescription fills for methotrexate within 1 year of the first RA diagnosis. The first RA diagnosis was the index date. Cases were matched 1:1 to controls on age, sex, region, year of index date, and length of baseline coverage. Statin users were defined by having \u22652 statin prescription fills at least 90 days pre-index. Patients identified as statin users were further classified by statin user status (current or former), statin use duration, and intensity of statin exposure. Odds ratios for RA risk with statin use were estimated using logistic regression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>16,363 RA cases and 16,363 matched controls were identified. Among RA cases, 5509 (33.7%) patients were statin users compared to 5164 (31.6%) of the controls. Statin users had a slightly increased risk of RA compared to non-users (OR 1.12, 95% CI 1.06\u20131.18), and former statin users had an increased RA risk compared to current users (OR 1.21, 95% CI 1.13\u20131.28). However, risk was eliminated following adjustment for hyperlipidemia. The risk estimates for statin use duration and intensity did not reach significance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study demonstrates no significant increase in the risk of developing RA for statin users compared to non-users after adjustment for hyperlipidemia in addition to other relevant confounders. However, more information from prospective studies would be necessary to further understand this relationship.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-021-02617-5","type":"journal-article","created":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T06:02:49Z","timestamp":1631944969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Risk of rheumatoid arthritis diagnosis in statin users in a large nationwide US study"],"prefix":"10.1186","volume":"23","author":[{"given":"Madeline N.","family":"Peterson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayley J.","family":"Dykhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia S.","family":"Crowson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"John M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey R.","family":"Sangaralingham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Myasoedova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,18]]},"reference":[{"issue":"17","key":"2617_CR1","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1001\/jama.2015.13766","volume":"314","author":"ED Kantor","year":"2015","unstructured":"Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. Jama. 2015;314(17):1818\u201331. https:\/\/doi.org\/10.1001\/jama.2015.13766.","journal-title":"Jama."},{"issue":"5519","key":"2617_CR2","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.1059344","volume":"292","author":"ES Istvan","year":"2001","unstructured":"Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001;292(5519):1160\u20134. https:\/\/doi.org\/10.1126\/science.1059344.","journal-title":"Science."},{"issue":"9364","key":"2617_CR3","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"PS Sever","year":"2003","unstructured":"Sever PS, Dahl\u00f6f B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149\u201358. https:\/\/doi.org\/10.1016\/S0140-6736(03)12948-0.","journal-title":"Lancet."},{"issue":"21","key":"2617_CR4","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195\u2013207. https:\/\/doi.org\/10.1056\/NEJMoa0807646.","journal-title":"N Engl J Med."},{"key":"2617_CR5","doi-asserted-by":"publisher","unstructured":"Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349-57. https:\/\/doi.org\/10.1056\/NEJM199811053391902.","DOI":"10.1056\/NEJM199811053391902"},{"issue":"20","key":"2617_CR6","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","volume":"279","author":"JR Downs","year":"1998","unstructured":"Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615\u201322. https:\/\/doi.org\/10.1001\/jama.279.20.1615.","journal-title":"JAMA."},{"issue":"1","key":"2617_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","volume":"45","author":"JK Liao","year":"2005","unstructured":"Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45(1):89\u2013118. https:\/\/doi.org\/10.1146\/annurev.pharmtox.45.120403.095748.","journal-title":"Annu Rev Pharmacol Toxicol."},{"issue":"2","key":"2617_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/art.21521","volume":"54","author":"AM Abeles","year":"2006","unstructured":"Abeles AM, Pillinger MH. Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy? Arthritis Rheum. 2006;54(2):393\u2013407. https:\/\/doi.org\/10.1002\/art.21521.","journal-title":"Arthritis Rheum."},{"issue":"9670","key":"2617_CR9","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","volume":"373","author":"PM Ridker","year":"2009","unstructured":"Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):1175\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(09)60447-5.","journal-title":"Lancet."},{"issue":"3","key":"2617_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.autrev.2017.10.013","volume":"17","author":"GM Li","year":"2018","unstructured":"Li GM, Zhao J, Li B, Zhang XF, Ma JX, Ma XL, et al. The anti-inflammatory effects of statins on patients with rheumatoid arthritis: a systemic review and meta-analysis of 15 randomized controlled trials. Autoimmun Rev. 2018;17(3):215\u201325. https:\/\/doi.org\/10.1016\/j.autrev.2017.10.013.","journal-title":"Autoimmun Rev."},{"issue":"1","key":"2617_CR11","first-page":"69","volume":"33","author":"S Lv","year":"2015","unstructured":"Lv S, Liu Y, Zou Z, Li F, Zhao S, Shi R, et al. The impact of statins therapy on disease activity and inflammatory factor in patients with rheumatoid arthritis: a meta-analysis. Clin Exp Rheumatol. 2015;33(1):69\u201376.","journal-title":"Clin Exp Rheumatol."},{"issue":"5","key":"2617_CR12","first-page":"964","volume":"34","author":"H Okamoto","year":"2007","unstructured":"Okamoto H, Koizumi K, Kamitsuji S, Inoue E, Hara M, Tomatsu T, et al. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J Rheumatol. 2007;34(5):964\u20138.","journal-title":"J Rheumatol."},{"issue":"8","key":"2617_CR13","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1191\/0961203303lu429oa","volume":"12","author":"C Abud-Mendoza","year":"2003","unstructured":"Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, Baranda L, Cruz-Rizo J, Gonz\u00e1lez-Amaro R. Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus. 2003;12(8):607\u201311. https:\/\/doi.org\/10.1191\/0961203303lu429oa.","journal-title":"Lupus."},{"issue":"9426","key":"2617_CR14","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(04)16449-0","volume":"363","author":"DW McCarey","year":"2004","unstructured":"McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet. 2004;363(9426):2015\u201321. https:\/\/doi.org\/10.1016\/S0140-6736(04)16449-0.","journal-title":"Lancet."},{"issue":"5","key":"2617_CR15","first-page":"Oc32","volume":"10","author":"K Mowla","year":"2016","unstructured":"Mowla K, Rajai E, Ghorbani A, Dargahi-Malamir M, Bahadoram M, Mohammadi S. Effect of atorvastatin on the disease activity and severity of rheumatoid arthritis: double-blind randomized controlled trial. J Clin Diagn Res. 2016;10(5):Oc32\u20136.","journal-title":"J Clin Diagn Res"},{"issue":"5","key":"2617_CR16","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1194\/jlr.M010876","volume":"52","author":"TT Tang","year":"2011","unstructured":"Tang TT, Song Y, Ding YJ, Liao YH, Yu X, Du R, et al. Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis. J Lipid Res. 2011;52(5):1023\u201332. https:\/\/doi.org\/10.1194\/jlr.M010876.","journal-title":"J Lipid Res."},{"issue":"1","key":"2617_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1468-3083.2006.01838.x","volume":"21","author":"B Noel","year":"2007","unstructured":"Noel B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol. 2007;21(1):17\u201324. https:\/\/doi.org\/10.1111\/j.1468-3083.2006.01838.x.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"5","key":"2617_CR18","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1136\/ard.2011.155622","volume":"71","author":"HJ de Jong","year":"2012","unstructured":"de Jong HJ, Klungel OH, van Dijk L, Vandebriel RJ, Leufkens HG, van der Laan JW, et al. Use of statins is associated with an increased risk of rheumatoid arthritis. Ann Rheum Dis. 2012;71(5):648\u201354. https:\/\/doi.org\/10.1136\/ard.2011.155622.","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"2617_CR19","doi-asserted-by":"publisher","first-page":"e0193297","DOI":"10.1371\/journal.pone.0193297","volume":"13","author":"HJI de Jong","year":"2018","unstructured":"de Jong HJI, Cohen Tervaert JW, Lalmohamed A, de Vries F, Vandebriel RJ, van Loveren H, et al. Pattern of risks of rheumatoid arthritis among patients using statins: a cohort study with the clinical practice research datalink. PLoS ONE. 2018;13(2):e0193297. https:\/\/doi.org\/10.1371\/journal.pone.0193297.","journal-title":"PLoS ONE."},{"issue":"9","key":"2617_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000336","volume":"7","author":"G Chodick","year":"2010","unstructured":"Chodick G, Amital H, Shalem Y, Kokia E, Heymann AD, Porath A, et al. Persistence with statins and onset of rheumatoid arthritis: a population-based cohort study. PLoS Med. 2010;7(9):e1000336. https:\/\/doi.org\/10.1371\/journal.pmed.1000336.","journal-title":"PLoS Med."},{"issue":"4","key":"2617_CR21","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1136\/ard.2008.091967","volume":"68","author":"SS Jick","year":"2009","unstructured":"Jick SS, Choi H, Li L, McInnes IB, Sattar N. Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis. 2009;68(4):546\u201351. https:\/\/doi.org\/10.1136\/ard.2008.091967.","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"2617_CR22","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1002\/art.39774","volume":"68","author":"K Tascilar","year":"2016","unstructured":"Tascilar K, Dell'Aniello S, Hudson M, Suissa S. Statins and risk of rheumatoid arthritis: a nested case-control study. Arthritis Rheumatol. 2016;68(11):2603\u201311. https:\/\/doi.org\/10.1002\/art.39774.","journal-title":"Arthritis Rheumatol."},{"issue":"may19 4","key":"2617_CR23","doi-asserted-by":"publisher","first-page":"c2197","DOI":"10.1136\/bmj.c2197","volume":"340","author":"J Hippisley-Cox","year":"2010","unstructured":"Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. Bmj. 2010;340(may19 4):c2197. https:\/\/doi.org\/10.1136\/bmj.c2197.","journal-title":"Bmj."},{"issue":"6","key":"2617_CR24","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.amjcard.2013.04.059","volume":"112","author":"T Schmidt","year":"2013","unstructured":"Schmidt T, Battafarano DF, Mortensen EM, Frei CR, Mansi I. Frequency of development of connective tissue disease in statin-users versus nonusers. Am J Cardiol. 2013;112(6):883\u20138. https:\/\/doi.org\/10.1016\/j.amjcard.2013.04.059.","journal-title":"Am J Cardiol."},{"issue":"1","key":"2617_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1365-2125.2008.03308.x","volume":"67","author":"L Smeeth","year":"2009","unstructured":"Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol. 2009;67(1):99\u2013109. https:\/\/doi.org\/10.1111\/j.1365-2125.2008.03308.x.","journal-title":"Br J Clin Pharmacol."},{"issue":"6","key":"2617_CR26","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.semarthrit.2020.03.008","volume":"50","author":"E Myasoedova","year":"2020","unstructured":"Myasoedova E, Karmacharya P, Duarte-Garcia A, Davis JM 3rd, Murad MH, Crowson CS. Effect of statin use on the risk of rheumatoid arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2020;50(6):1348\u201356. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.03.008.","journal-title":"Semin Arthritis Rheum."},{"key":"2617_CR27","unstructured":"OptumLabs. OptumLabs Data Warehouse (OLDW) Descriptions and Citation. Cambridge, MA 2019."},{"issue":"24","key":"2617_CR28","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2019;73(24):3168\u2013209. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.002.","journal-title":"Journal of the American College of Cardiology."},{"issue":"5","key":"2617_CR29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8.","journal-title":"J Chronic Dis."},{"issue":"1","key":"2617_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Medical care. 1998;36(1):8\u201327. https:\/\/doi.org\/10.1097\/00005650-199801000-00004.","journal-title":"Medical care."},{"issue":"2","key":"2617_CR31","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1164\/rccm.201902-0456OC","volume":"200","author":"TM Dempsey","year":"2019","unstructured":"Dempsey TM, Sangaralingham LR, Yao X, Sanghavi D, Shah ND, Limper AH. Clinical effectiveness of antifibrotic medications for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2019;200(2):168\u201374. https:\/\/doi.org\/10.1164\/rccm.201902-0456OC.","journal-title":"Am J Respir Crit Care Med."},{"issue":"6911","key":"2617_CR32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nature01158","volume":"420","author":"S Youssef","year":"2002","unstructured":"Youssef S, St\u00fcve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420(6911):78\u201384. https:\/\/doi.org\/10.1038\/nature01158.","journal-title":"Nature."},{"issue":"6","key":"2617_CR33","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.tcm.2005.07.002","volume":"15","author":"C Arnaud","year":"2005","unstructured":"Arnaud C, Braunersreuther V, Mach F. Toward immunomodulatory and anti-inflammatory properties of statins. Trends in Cardiovascular Medicine. 2005;15(6):202\u20136. https:\/\/doi.org\/10.1016\/j.tcm.2005.07.002.","journal-title":"Trends in Cardiovascular Medicine."},{"issue":"3","key":"2617_CR34","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/rheumatology\/keh035","volume":"43","author":"B No\u00ebl","year":"2004","unstructured":"No\u00ebl B. Statins and lupus erythematosus. Rheumatology. 2004;43(3):397\u20138.","journal-title":"Rheumatology."},{"issue":"7","key":"2617_CR35","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/jcp.56.7.481","volume":"56","author":"CC Mok","year":"2003","unstructured":"Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003;56(7):481\u201390. https:\/\/doi.org\/10.1136\/jcp.56.7.481.","journal-title":"J Clin Pathol."},{"issue":"8","key":"2617_CR36","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.it.2009.05.005","volume":"30","author":"S Kivity","year":"2009","unstructured":"Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y. Infections and autoimmunity \u2013 friends or foes? Trends Immunol. 2009;30(8):409\u201314. https:\/\/doi.org\/10.1016\/j.it.2009.05.005.","journal-title":"Trends Immunol."},{"issue":"3","key":"2617_CR37","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1006\/bbrc.1994.2861","volume":"205","author":"KD Jones","year":"1994","unstructured":"Jones KD, Couldwell WT, Hinton DR, Su YH, He SK, Anker L, et al. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochem Biophys Res Commun. 1994;205(3):1681\u20137. https:\/\/doi.org\/10.1006\/bbrc.1994.2861.","journal-title":"Biochem Biophys Res Commun."},{"issue":"1","key":"2617_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0021-9150(01)00613-X","volume":"161","author":"LM Blanco-Colio","year":"2002","unstructured":"Blanco-Colio LM, Villa A, Ortego M, Hern\u00e1ndez-Presa MA, Pascual A, Plaza JJ, et al. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis. 2002;161(1):17\u201326. https:\/\/doi.org\/10.1016\/S0021-9150(01)00613-X.","journal-title":"Atherosclerosis."},{"issue":"9","key":"2617_CR39","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S0301-472X(03)00192-9","volume":"31","author":"D Chapman-Shimshoni","year":"2003","unstructured":"Chapman-Shimshoni D, Yuklea M, Radnay J, Shapiro H, Lishner M. Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Exp Hematol. 2003;31(9):779\u201383. https:\/\/doi.org\/10.1016\/S0301-472X(03)00192-9.","journal-title":"Exp Hematol."},{"issue":"4","key":"2617_CR40","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/sj.leu.2402476","volume":"16","author":"WWL Wong","year":"2002","unstructured":"Wong WWL, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002;16(4):508\u201319. https:\/\/doi.org\/10.1038\/sj.leu.2402476.","journal-title":"Leukemia."},{"issue":"1","key":"2617_CR41","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0021-9150(99)00462-1","volume":"152","author":"AC Knapp","year":"2000","unstructured":"Knapp AC, Huang J, Starling G, Kiener PA. Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. Atherosclerosis. 2000;152(1):217\u201327. https:\/\/doi.org\/10.1016\/S0021-9150(99)00462-1.","journal-title":"Atherosclerosis."},{"issue":"5","key":"2617_CR42","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1046\/j.1365-2133.2001.04182.x","volume":"144","author":"B Baima","year":"2001","unstructured":"Baima B, Sticherling M. Apoptosis in different cutaneous manifestations of lupus erythematosus. Br J Dermatol. 2001;144(5):958\u201366. https:\/\/doi.org\/10.1046\/j.1365-2133.2001.04182.x.","journal-title":"Br J Dermatol."},{"issue":"8","key":"2617_CR43","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/1529-0131(200008)43:8<1663::AID-ANR1>3.0.CO;2-1","volume":"43","author":"P Rovere","year":"2000","unstructured":"Rovere P, Sabbadini MG, Fazzini F, Bondanza A, Zimmermann VS, Rugarli C, et al. Remnants of suicidal cells fostering systemic autoaggression: apoptosis in the origin and maintenance of autoimmunity. Arthritis & Rheumatism. 2000;43(8):1663\u201372. https:\/\/doi.org\/10.1002\/1529-0131(200008)43:8<1663::AID-ANR1>3.0.CO;2-1.","journal-title":"Arthritis & Rheumatism."},{"issue":"2","key":"2617_CR44","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1136\/ard.2006.051672","volume":"66","author":"V Van Halm","year":"2007","unstructured":"Van Halm V, Nielen M, Nurmohamed M, Van Schaardenburg D, Reesink H, Voskuyl A, et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis. 2007;66(2):184\u20138. https:\/\/doi.org\/10.1136\/ard.2006.051672.","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"2617_CR45","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1161\/ATVBAHA.107.159749","volume":"28","author":"A Alipour","year":"2008","unstructured":"Alipour A, van Oostrom AJ, Izraeljan A, Verseyden C, Collins JM, Frayn KN, et al. Leukocyte activation by triglyceride-rich lipoproteins. Arterioscler Thromb Vasc Biol. 2008;28(4):792\u20137. https:\/\/doi.org\/10.1161\/ATVBAHA.107.159749.","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"1","key":"2617_CR46","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.atherosclerosis.2004.07.004","volume":"177","author":"A Van Oostrom","year":"2004","unstructured":"Van Oostrom A, Rabelink T, Verseyden C, Sijmonsma T, Plokker H, De Jaegere PT, et al. Activation of leukocytes by postprandial lipemia in healthy volunteers. Atherosclerosis. 2004;177(1):175\u201382. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2004.07.004.","journal-title":"Atherosclerosis."},{"issue":"5","key":"2617_CR47","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1161\/01.ATV.0000014079.98335.72","volume":"22","author":"S Meijssen","year":"2002","unstructured":"Meijssen S, Van Dijk H, Verseyden C, Erkelens D, Cabezas MC. Delayed and exaggerated postprandial complement component 3 response in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 2002;22(5):811\u20136. https:\/\/doi.org\/10.1161\/01.ATV.0000014079.98335.72.","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"6","key":"2617_CR48","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/art.1780370606","volume":"37","author":"KW Chan","year":"1994","unstructured":"Chan KW, Felson DT, Yood RA, Walker AM. The lag time between onset of symptoms and diagnosis of rheumatoid arthritis. Arthritis Rheum. 1994;37(6):814\u201320. https:\/\/doi.org\/10.1002\/art.1780370606.","journal-title":"Arthritis Rheum."},{"issue":"nov06 3","key":"2617_CR49","doi-asserted-by":"publisher","first-page":"a2286","DOI":"10.1136\/bmj.a2286","volume":"337","author":"S Sathasivam","year":"2008","unstructured":"Sathasivam S, Lecky B. Statin induced myopathy. Bmj. 2008;337(nov06 3):a2286. https:\/\/doi.org\/10.1136\/bmj.a2286.","journal-title":"Bmj."},{"issue":"11","key":"2617_CR50","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1002\/art.1780401106","volume":"40","author":"DP Symmons","year":"1997","unstructured":"Symmons DP, Bankhead CR, Harrison BJ, Brennan P, Barrett EM, Scott DG, et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum. 1997;40(11):1955\u201361. https:\/\/doi.org\/10.1002\/art.1780401106.","journal-title":"Arthritis Rheum."},{"issue":"1","key":"2617_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-015-0560-2","volume":"17","author":"D Di Giuseppe","year":"2015","unstructured":"Di Giuseppe D, Bottai M, Askling J, Wolk A. Physical activity and risk of rheumatoid arthritis in women: a population-based prospective study. Arthritis Res Ther. 2015;17(1):1\u20137.","journal-title":"Arthritis Res Ther."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02617-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-021-02617-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02617-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T06:04:59Z","timestamp":1631945099000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02617-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,18]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2617"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02617-5","relation":{},"ISSN":["1478-6362"],"issn-type":[{"type":"electronic","value":"1478-6362"}],"subject":[],"published":{"date-parts":[[2021,9,18]]},"assertion":[{"value":"25 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institution Review Board approval was not required for this study, as all data have been de-identified.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests relevant to the current study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"244"}}